SLC5A2 and otitis media with effusion: Others criticized that the study (Teerlink et al. 2020) was performed with only 2.5% of the patients taking SGLT2 inhibitors which are now strongly recommended in systolic heart failure guidelines because they reduce mortality, and therefore the study findings remained inconclusive because in the presence of SGLT2 inhibitors, no additional effect of OME might be noticeable, and at least the study design was in this regard outdated and would not help in directing nowadays the optimal drug treatment (Bellumkonda 2021).